Next Generation Cardiovascular Treatments via Inhaled Nano‑in‑Micro Technology
NanoPhoria Bioscience is a preclinical-stage biotechnology company
We are pioneering the next generation of cardiovascular treatments through our innovative inhaled, Nano-in-Micro delivery platform.
Our mission is to transform the way therapeutics are delivered, enabling precise, tissue-directed treatment for patients with cardiovascular conditions.
HFrEF, a Disease of High Unmet Medical Need with Huge Economic Impact
30m
patients
An estimated 30m patients worldwide suffer from Heart Failure with Reduced Ejection Fraction
>60%
mortality rate
Despite advances, 5-year mortalityrate still stands at over 60% and has been increasing in recent years
will cost
$70bn
Heart failure is set to cost the US healthcare system $70bn by 2030
THERAPEUTIC FOCUS
Advancing Care for Patients Suffering from Heart Failure with Reduced Ejection Fraction (HFrEF)
Learn more...
PLATFORM
At the core of our delivery technology is a proprietary Nano-in-Micro platform built on inorganic Calcium Phosphate (CaP) nanoparticles
Learn more...
LATEST NEWS
12 January 2026
NanoPhoria Announces Second Close of its Series A Round, Now with Participation from European Innovation Council Fund
LATEST PUBLICATION
28 January 2026
One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge
Stephen J. Greene, Haolin Xu, Karen Chiswell, et al